Measuring ADC Reductions as an Early Response to Chemotherapeutic Treatment

Using Dynamic Contrast Enhanced MRI and Immunohistochemistry to Monitor Tumour Response to Tirapazamine, a Hypoxia-Targeting Chemotherapeutic Agent